Asco 2025 · Posters · Cáncer de Mama ·
Antonio Llombart-Cussac, MD, PhD
Asco 2025 · Posters · Cáncer de Mama ·
Antonio Llombart-Cussac, MD, PhD
Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) measured by Guardant Reveal in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with long-term disease control on first-line trastuzumab-pertuzumab.
